AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).

doi:10.1200/JCO.2021.39.15_suppl.TPS9128

	AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).
	Socinski, Mark A.; Spira, Alexander I.; Paz-Ares, Luis G.; Reck, Martin ; Lu, Shun ; Nishio, Makoto ; Li, Jiang ; Zhou, Yunfei ; Rhee, Joon Whan ; Duque, Sandra Chica
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2021-05-20
卷号	39
ISSN号	0732-183X
DOI	10.1200/JCO.2021.39.15_suppl.TPS9128
资助项目	BeiGene, Ltd. - BeiGene, Ltd
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000708120307040
资助机构	BeiGene, Ltd. - BeiGene, Ltd
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/126500]
专题	中国科学院合肥物质科学研究院
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 2.Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan 3.Shanghai Chest Hosp, Shanghai, Peoples R China 4.German Ctr Lung Res, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany 5.Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain 6.NYU, US Oncol Network, US Oncol Res, Virginia Canc Specialists, Fairfax, VA USA 7.Advent Hlth Hematol & Oncol, Orlando, FL USA 8.Zhejiang Canc Hosp, Hangzhou, Peoples R China 9.BeiGene US Co Ltd, San Mateo, CA USA
推荐引用方式 GB/T 7714	Socinski, Mark A.,Spira, Alexander I.,Paz-Ares, Luis G.,et al. AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA	Socinski, Mark A..,Spira, Alexander I..,Paz-Ares, Luis G..,Reck, Martin.,Lu, Shun.,...&Yu, Xinmin.(2021).AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC)..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA	Socinski, Mark A.,et al."AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).".JOURNAL OF CLINICAL ONCOLOGY 39(2021).